Contemporary costs of HIV healthcare in the HAART era

AIDS

Volumn 24, Issue 17, 2010, Pages 2705-2715

  Gebo, Kelly A ^a   Fleishman, John A ^b   Conviser, Richard ^c   Hellinger, James ^d   Hellinger, Fred J ^b   Josephs, Joshua S ^a   Keiser, Philip ^e   Gaist, Paul ^f   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c Global Health Policy Partners   (United States)

^d Community Medical Alliance ^*  (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD4 cell count; cost; HAART; HIV; HIV Research Network; utilization

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG;

ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICARE; OPPORTUNISTIC INFECTION; OUTPATIENT CARE; PNEUMOCYSTIS PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SURVIVAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DELIVERY OF HEALTH CARE; FEMALE; HIV INFECTIONS; HUMANS; MALE; UNITED STATES;

EID: 78349312874     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833f3c14     Document Type: Article

References (43)

1. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344:817-823.
2. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987; 102: 5-17.
3. Scitovsky AA, Cline M, Lee PR. Medical care costs of patients with AIDS in San Francisco. JAMA 1986; 256:3103-3106.
4. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antire-troviral therapy. AIDS 1999; 13:963-969.
5. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Mathews WC, Korthuis PT, et al. Hospital and outpatient health services utilization among HIV-infected patients in care 2000-2002. Med Care 2005; 43 (9 Suppl):III40-III52.
6. Hellinger FJ, Fleishman JA. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr 2000; 24:182-188.
7. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active anti-retroviral therapy. JAcquir Immune Defic Syndr 2001; 27:143-152.
8. Hellinger FJ. Forecasting the medical care costs of the HIV epidemic: 1991-1994. Inquiry 1991; 28:213-225.
9. Hellinger FJ. Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry 1992; 29:356-365.
10. Hellinger FJ. The use of health services by women with HIV infection. Health Serv Res 1993; 28:543-561.
11. Hellinger FJ. Cost and financing of care for persons with HIV disease: an overview. Healthcare Financ Rev 1998; 19: 5-18.
12. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, et al. Distribution of healthcare expenditures for HIV-infected patients. Clin Infect Dis 2006; 42:1003-1010.
13. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, Del Rio C, Kamimoto L, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 2006; 43:451-457.
14. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunode-ficiency virus care in the United States. Med Care 2006; 44:990-997.
15. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infec-tion. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
16. Moore RD, Chaisson RE. Natural history of HIVinfection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-1942.
17. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336:1531-1532.
18. The HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002; 30:21-26.
19. Gebo K, Fleishman J, Conviser R, Reilly E, Korthuis P, Hellinger J, et al. Racial and gender disparities in receipt of HAART persist in a multistate sampleof HIV patients in 2001.JAcquir Immune Defic Syndr 2005; 38:96-103.
20. Gebo KA, Fleishman JA, Reilly ED, Moore RD, and The HIV Research Network. High rates of primary mycobacterium avium complex and Pneumocystisjiroveci prophylaxis in the United States. Med Care 2005; 43 (9 Suppl):III23-III30.
21. Steiner C, Elixhauser A, Schnaier J. The healthcare cost and utilization project: an overview. Eff Clin Pract 2002; 5:143-151.
22. Friedman B, Basu J. The rate and cost of hospital readmissions for preventable conditions. Med Care Res Rev 2004; 61:225-240.
23. Fleishman JA, Hellinger FJ. Trends in HIV-related inpatient admissions from 1993 to 1997: a seven-state study. JAcquir Immune Defic Syndr 2001; 28:73-80.
24. Fleishman JA, Hellinger FH. Recent trends in HIV-related inpatient admissions 1996-2000: a 7-state study. J Acquir Immune Defic Syndr 2003; 34:102-110.
25. U.S. Department of Health and Human Services, Office of Inspector General. AIDS Drug Assistance Program costcontain-mentstrategies; September2000. Report No. OEI-05-99-00610.
26. Congressional Budget Office.Pricesforbrand-namedrugsunder selected federal programs. June 2005.
27. Office of Inspector General. Department of Health and Human Services. Medicaid drug price comparisons: average manufac-turer price to published prices; June 2005. Report No. OEI-05-05-00240. [Accessed November 2006]
28. Centers for Medicare and Medicaid Services. Physician Fee Schedule Search. http://www.cms.hhs.gov/PFSlookup/02- PFSSearch.asp. [Accessed 21 July 2009]
29. Ellis RP, Ash A. Refinements to the diagnostic cost group model. Inquiry 1995; 32:1-12.
30. Manning WG, Mullahy J. Estimatinglogmodels: to transform or not to transform. J Health Econ 2001; 20:461-494.
31. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare Expenditures. J Health Econ 2004; 23:525-542.
32. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models.J Health Econ 1999; 18:153-171.
33. Steinbrook R. Providing antiretroviral therapy for HIV infec-tion. N Engl J Med 2001; 344:844-846.
34. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34:165-173.
35. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-1471.
36. Mocroft A, Monforte A, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, et al. Changes in hospital admissions across Europe: 1995-2003. Results from the Euro SIDA study. HIV Med 2004; 5:437-447.
37. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for meta-bolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005; 40:609-616.
38. Betz M, Gebo KA, Barber E, Sklar P, Fleishman JA, Reilly ED, et al. Patterns of diagnoses in hospital admissions in a multi-state cohort of HIV+ adults in 2001. Med Care 2005; 43 (9 Suppl):III13-III14.
39. Himelhoch S, Chander G, Dilonardo J, Gebo KA. Hospital service utilization among HIV infected patients with co-occur-ring serious mental illness and injection drug use receiving outpatient HIV care [abstract]. In: 12th Conference on Retro-viruses and Opportunistic Infections; Boston, MA; February 2005.
40. Ship JA, Wolff A, Selik RM. Epidemiology ofacquired immune deficiency syndrome in persons aged 50 years or older.JAcquir Immune Defic Syndr 1991; 4:84-88.
41. Centers for Disease Control and Prevention. HIV/AIDS surveil- lancesupplementalreport; 2002. Report No. 13. pp. 1-44.
42. Centers for Disease Control and Prevention. AIDS among per-sonsaged morethan or = 50 years: United States, 1991-1996. MMWR Morb Mortal Wkly Rep 1998; 47:21-27.
43. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother 2006; 57:4-7.